Dan Petrylak, MD, presents our first case for discussion, an 80-year-old man with metastatic castration-sensitive prostate cancer (mCSPC). Front-line therapy options and monitoring for mCSPC are also mentioned.
Case Studies: An 80-Year-Old Man, As Well As a 62-Year-Old Man, With Metastatic Castration-Sensitive Prostate Cancer
Dr Petrylak recalls the study design and results of the TITAN study.
An expert explains the unmet needs in the mCSPC landscape, as well as key takeaways if you are treating patients with this disease.
Dr Petrylak presents our second case, a 62-year-old man with mCSPC.
Dan Petrylak, MD, discusses the pros and cons of using abiraterone as a front-line therapy for mCSPC and provides details of the PEACE-1 study.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
